

NEWS RELEASE

INOVIO to Participate in Upcoming Investor Conferences in May

4/29/2024

PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May:

The Citizens JMP Life Sciences Conference

Date: Tuesday, May 14, 2024

Time: 11:30 AM ET

Presenter: Dr. Jacqueline Shea, President & CEO

Format: Fireside Chat

RBC Capital Markets 2024 Global Healthcare Conference

Date: Wednesday, May 15, 2024

Time: 10:00 AM ET

Presenter: Dr. Jacqueline Shea, President & CEO

Format: Fireside Chat

H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Date: Monday, May 20, 2024

Time: 12:30 PM ET

Presenter: Dr. Jacqueline Shea, President & CEO

Format: Fireside Chat

During the conferences, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.

Webcasts of the fireside chats will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. Replays of the webcasts will be available for 90 days after the date of the presentation.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-investor-conferences-in-may-302129665.html

SOURCE INOVIO Pharmaceuticals, Inc.